Filing Details

Accession Number:
0000921895-20-002471
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-23 19:26:48
Reporting Period:
2020-09-21
Accepted Time:
2020-09-23 19:26:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
791908 Xoma Corp XOMA Pharmaceutical Preparations (2834) 522154066
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
918923 P L Fund Value Biotechnology 44 Montgomery Street
40Th Floor
San Francisco CA 94104
No No Yes No
1055947 P/il L Partners Bvf 44 Montgomery Street
40Th Floor
San Francisco CA 94104
Yes No Yes Yes
1056807 Bvf Inc/il 44 Montgomery Street
40Th Floor
San Francisco CA 94104
No No Yes No
1102444 Biotechnology Value Fund Ii Lp 44 Montgomery Street
40Th Floor
San Francisco CA 94104
No No Yes No
1233840 N Mark Lampert 44 Montgomery Street
40Th Floor
San Francisco CA 94104
No No Yes No
1660683 Biotechnology Value Trading Fund Os Lp P.o. Box 309 Ugland House
Grand Cayman E9 KY1-1104
No No No Yes
1660684 Ltd. Os Partners Bvf P.o. Box 309 Ugland House
Grand Cayman E9 KY1-1104
No No No Yes
1803805 Bvf I Gp Llc 44 Montgomery St., 40Th Floor
San Francisco CA 94104
No No Yes No
1803806 Bvf Ii Gp Llc 44 Montgomery St., 40Th Floor
San Francisco CA 94104
No No Yes No
1803809 Bvf Gp Holdings Llc 44 Montgomery St., 40Th Floor
San Francisco CA 94104
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.0075 Par Value Per Share Acquisiton 2020-09-21 12,259 $18.39 2,023,276 No 4 P Direct
Common Stock, $0.0075 Par Value Per Share Acquisiton 2020-09-22 6,960 $18.45 2,030,236 No 4 P Direct
Common Stock, $0.0075 Par Value Per Share Acquisiton 2020-09-23 9,888 $18.20 2,040,124 No 4 P Direct
Common Stock, $0.0075 Par Value Per Share Acquisiton 2020-09-21 10,069 $18.39 1,738,512 No 4 P Direct
Common Stock, $0.0075 Par Value Per Share Acquisiton 2020-09-22 4,991 $18.45 1,743,503 No 4 P Direct
Common Stock, $0.0075 Par Value Per Share Acquisiton 2020-09-23 7,201 $18.20 1,750,704 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, $0.0075 Par Value Per Share 159,537 Direct
Common Stock, $0.0075 Par Value Per Share 231,878 Indirect See footnote
Common Stock, $0.0075 Par Value Per Share 11,799 Indirect See footnote
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock, $0.0075 Par Value Per Share Series X Convertible Preferred Stock $0.00 2,313,000 2,313 Direct
Common Stock, $0.0075 Par Value Per Share Series X Convertible Preferred Stock $0.00 1,506,000 1,506 Direct
Common Stock, $0.0075 Par Value Per Share Series X Convertible Preferred Stock $0.00 412,000 412 Direct
Common Stock, $0.0075 Par Value Per Share Series X Convertible Preferred Stock $0.00 772,000 772 Indirect
Common Stock, $0.0075 Par Value Per Share Non-Qualified Stock Option (right to buy) $21.27 2030-05-20 6,152 6,152 Indirect
Common Stock, $0.0075 Par Value Per Share Non-Qualified Stock Option (right to buy) $15.59 2029-05-16 8,167 8,167 Indirect
Common Stock, $0.0075 Par Value Per Share Non-Qualified Stock Option (right to buy) $25.16 2028-05-17 5,052 5,052 Indirect
Common Stock, $0.0075 Par Value Per Share Non-Qualified Stock Option (right to buy) $4.67 2027-03-02 15,222 15,222 Indirect
Expiration Date Amount Remaning Holdings Nature of Ownership
2,313,000 2,313 Direct
1,506,000 1,506 Direct
412,000 412 Direct
772,000 772 Indirect
2030-05-20 6,152 6,152 Indirect
2029-05-16 8,167 8,167 Indirect
2028-05-17 5,052 5,052 Indirect
2027-03-02 15,222 15,222 Indirect
Footnotes
  1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
  2. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
  3. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
  4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
  5. Securities held in certain Partners managed accounts (the "Partners Managed Accounts"). Partners, as the investment manager of the Partners Managed Accounts, may be deemed to beneficially own the securities held by the Partners Managed Accounts. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Accounts. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Accounts.
  6. The Series X Convertible Preferred Stock may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d), more than 19.99% of the shares of Common Stock outstanding immediately after giving effect to such exercise. The Series X Convertible Preferred Stock does not have an expiration date. The initial conversion price is $4.03 and is subject to certain adjustments pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock.
  7. Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Matthew D. Perry, who serves on the Issuer's board of directors and as President of Partners, pursuant to which Mr. Perry is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Perry disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
  8. The shares subject to this option shall vest and become exercisable in equal monthly installments over the 12-month period following the date of grant (May 20, 2020), provided that the final installment will occur on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option.
  9. All of the shares subject to this option vested and became exercisable in twelve equal monthly installments. As of May 16, 2020, these options are fully exercisable.
  10. These options were acquired pursuant to a grant of stock options under the Amended and Restated XOMA Corporation 2010 Long Term Incentive and Stock Award Plan (the "Plan") and were scheduled to vest and become exercisable on the one-year anniversary of the grant date of May 17, 2018. As of May 17, 2019, these options are fully exercisable.
  11. These options were acquired pursuant to the Plan, and were exercisable in twelve equal monthly installments, beginning one month from the vesting commencement date, which was February 15, 2017. As of February 15, 2018, these options are fully exercisable.